Single-institution real-life experience of 177Lu-DOTATATE treatment in progressive, well-differentiated GEP-NETs

#3230

Introduction: -

Aim(s): To evaluate safety, toxicity, interim efficacy of 177Lu-DOTATATE (PPRT) in progressive G1-G2 GEP-NETs.

Materials and methods: We prospectively evaluated GEP-NET treated with PRRT at our institution from 04/2019 to 04/2020. PRRT was given as 4 infusions, 7.4 GBq each. To evaluate the interim response, CT/MRI were performed after the second PRRT. Side effects were assessed applying CTCAE; RECIST 1.1 were applied to evaluate interim response.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Federica S

Authors: Scalorbi F, Maccauro M, Lorenzoni A, Fuoco V, Argiroffi G,

Keywords: GEP-NET, G1, G2, PRRT, 117Lu-DOTA peptides, toxicity, interim evaluation,